A141080 Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
LigaChem Biosciences Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩92,500.00 |
52 Week High | ₩95,000.00 |
52 Week Low | ₩32,400.00 |
Beta | 1.04 |
11 Month Change | 15.48% |
3 Month Change | 40.79% |
1 Year Change | 155.17% |
33 Year Change | 78.92% |
5 Year Change | 309.29% |
Change since IPO | 957.14% |
Recent News & Updates
Recent updates
Here's Why LigaChem Biosciences (KOSDAQ:141080) Can Manage Its Debt Despite Losing Money
May 23A Look At The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Mar 29What Kind Of Shareholders Hold The Majority In LegoChem Biosciences, Inc.'s (KOSDAQ:141080) Shares?
Jan 28Estimating The Fair Value Of LegoChem Biosciences, Inc. (KOSDAQ:141080)
Dec 07Shareholder Returns
A141080 | KR Life Sciences | KR Market | |
---|---|---|---|
7D | 10.9% | 7.9% | 7.9% |
1Y | 155.2% | 22.4% | -0.5% |
Return vs Industry: A141080 exceeded the KR Life Sciences industry which returned 22.4% over the past year.
Return vs Market: A141080 exceeded the KR Market which returned -0.5% over the past year.
Price Volatility
A141080 volatility | |
---|---|
A141080 Average Weekly Movement | 9.5% |
Life Sciences Industry Average Movement | 8.6% |
Market Average Movement | 6.4% |
10% most volatile stocks in KR Market | 11.9% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A141080's share price has been volatile over the past 3 months.
Volatility Over Time: A141080's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 145 | Yong Kim | www.legochembio.com |
LigaChem Biosciences Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules.
LigaChem Biosciences Inc. Fundamentals Summary
A141080 fundamental statistics | |
---|---|
Market cap | ₩3.37t |
Earnings (TTM) | -₩46.54b |
Revenue (TTM) | ₩57.54b |
58.6x
P/S Ratio-72.4x
P/E RatioIs A141080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A141080 income statement (TTM) | |
---|---|
Revenue | ₩57.54b |
Cost of Revenue | ₩15.79b |
Gross Profit | ₩41.75b |
Other Expenses | ₩88.30b |
Earnings | -₩46.54b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.28k |
Gross Margin | 72.56% |
Net Profit Margin | -80.88% |
Debt/Equity Ratio | 1.9% |
How did A141080 perform over the long term?
See historical performance and comparison